Trials / Not Yet Recruiting
Not Yet RecruitingNCT05960864
Chinese Spondyloarthritis Inception Cohort (CESPIC)
Chinese Spondyloarthritis Inception Cohort
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,000 (estimated)
- Sponsor
- Southwest Hospital, China · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The Chinese Spondyloarthritis Inception cohort (CESPIC) was started 2000 as a prospective, longitudinal, multicentre, nationwide study in China on patients with early SpA including ankylosing spondylitis (AS, also known as radiographic axial spondyloarthritis) and non-radiographic axial SpA. The objectives of CESPIC are to learn about the course of SpA during the very early stage of the disease, to appropriately assess the outcome including radiographic progression of patients after several years of follow-up, to identify outcome predictors, to assess quality of life, function, and costs (direct and indirect costs). CESPIC has been recently expanded to recruit patients with other forms of SpA / conditions associated with SpA: reactive arthritis, acute anterior uveitis, Crohn's disease as well as with psoriasis / axial psoriatic arthritis.
Conditions
- Ankylosing Spondylitis (AS) / Radiographic Axial SpA (r-axSpA)
- Non-radiographic Axial Spondyloarthritis (Nr-axSpA)
- Axial Psoriatic Arthritis (axPsA)
- Acute Anterior Uveitis (AAU)
- Crohn Disease (CD)
- Ulcerative Colitis (UC)
- Reactive Arthritis (ReA)
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Celecoxib | If we find any behavior that affects the safety of patients in the experiment, we will stop |
Timeline
- Start date
- 2024-09-01
- Primary completion
- 2025-08-01
- Completion
- 2030-08-01
- First posted
- 2023-07-27
- Last updated
- 2024-04-17
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05960864. Inclusion in this directory is not an endorsement.